Closing Bell Closing Bell: 5/9/25
May 9, 2025
Michelle Ross, CIO of StemPoint Capital and expert in biotech investments, shares insights on the evolving healthcare landscape. She tackles the complexities of drug pricing in the U.S., balancing innovation with affordability. The discussion highlights potential regulatory changes affecting investor sentiment and market dynamics. Ross also explores exciting investment opportunities in rare diseases and oncology firms while examining the impact of upcoming FDA approvals on stock performance.
AI Snips
Chapters
Transcript
Episode notes
Tariff Reduction Uncertainty
- President Trump floated cutting U.S. tariffs on Chinese imports from 145% to 80%, but the White House insists no unilateral tariff reduction without Chinese concessions.
- Markets are cautiously optimistic, pricing in incremental improvements but not expecting major breakthroughs this weekend.
Market Rally's Mixed Drivers
- The recent market rally reflects incremental positive news and eased crisis fears, not clarity on tariffs or policy.
- Earnings guidance was better than expected, adding relief, but tariff resolutions remain uncertain.
Tariff Impact and Market Froth
- The peak tariff uncertainty may have passed with possible tariff cuts to below 80%, but 80% remains prohibitive for doing business.
- The market's recent gains owe more to AI spending optimism and frothy pockets like Bitcoin than tariff resolutions.